Pfizer Inc. (NYSE:PFE) and X-Chem, which is a privately owned biotechnology company, on June 11, 2014 announced that they entered into a multi-target collaboration with each other. The main objective of the collaboration is potential development of various programs for treating orphan and inflammatory diseases. The financial details of the agreement between the two were not unveiled. Pfizer Inc. (NYSE:PFE) net profit margin is 81.20% and weekly performance is 0.37%. On last trading day company shares ended up $29.53. Analysts mean target price for the company is $34.55. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is -1.5 %.
June 11, 2014 — Patients with Parkinson’s disease (PD) treated with the Boston Scientific Corporation (NYSE:BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent improvement in motor scores, according to the latest one-year data. Boston Scientific Corporation (NYSE:BSX) ended the day on $12.80. Gross Margin is 70.20% and its return on assets is 2.20%. Boston Scientific Corporation (NYSE:BSX) quarterly performance is -1.61%.
Drugmaker Merck & Co. Inc. (NYSE:MRK) has narrowed its research focus in the hope of raising profit, but type 2 diabetes remains part of the program because the market is huge and will likely grow as Americans and people in other countries get older and heavier. Merck & Co., Inc. (NYSE:MRK) shares moved down -0.10% in last trading session and was closed at $58.24, while trading in range of $57.98 – $58.65. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 18.16%.
Many investors appear to be quite bearish on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) especially if you look at the percentage of the float that is sold short for this stock. Currently, 22.91% of the float is sold short, suggesting an extreme level of bearishness for ARIA, according to Zack. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) ended the last trading day at $6.38. Company weekly volatility is calculated as 4.56% and price to cash ratio as 6.51. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a negative weekly performance of -4.63%.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) a clinical-stage pharmaceutical company, announced initial Phase 1 data from patients with multiple myeloma treated with Karyopharm’s lead selective inhibitor of nuclear export (SINE), Selinexor (KPT-330), in combination with “low-dose” (20 mg twice weekly) dexamethasone. Among eight patients, the best responses were one stringent complete response (sCR), three partial responses (PRs), two minor responses (MRs), one progressive disease and one non-evaluable. Accordingly, the clinical benefit response rate (sCR+PR+MR) is 75% and the overall response rate (sCR+PR) is 50%. Karyopharm Therapeutics Inc (NASDAQ:KPTI) weekly performance is 87.21%. On last trading day company shares ended up $47.12. Analysts mean target price for the company is $48.25. Karyopharm Therapeutics Inc (NASDAQ:KPTI) distance from 50-day simple moving average (SMA50) is 68.37%.